Cannabidiol for the treatment of psychosis in Parkinson’s disease.

Author(s): Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V

Department of Neuropsychiatry and Medical Psychology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. [email protected]

Subject: Parkinson's Disease View the study


The management of psychosis in Parkinson's disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective effect of Cannabidiol (CBD) has been suggested. Therefore, the aim of the present study was to directly evaluate for the first time, the efficacy, tolerability and safety of CBD on PD patients with psychotic symptoms. This was an open-label pilot study.

Source: Journal of Psychopharmacology (Price: $40)
Share Tweet

More medical studies related to Parkinson's Disease:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.